A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of the study is to characterize safety of JNJ-68284528 and establish the
recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528
(Phase 2).

本研究旨在表征JNJ-68284528的安全性，确定其1b期阶段的推荐II期剂量（Recommended Phase 2 Dose，RP2D），并评估JNJ-68284528在II期阶段的疗效。